Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma

详细信息    查看全文

• 作者：Adaleta Mulaomerovi&#x107 ; Alma Halilbaš ; i&#x107 ; Elmir &#x10c ; i&#x10d ; kuš ; i&#x107 ; Tina Zavaš ; nik-Bergant ; Lejla Begi&#x107 ; ; Janko Kos
• 关键词：Cystatin C ; Non-Hodgkin lymphoma ; Relapse ; Dendritic cells
• 刊名：Cancer Letters
• 出版年：2007
• 出版时间：18 April 2007
• 年：2007
• 卷：248
• 期：2
• 页码：192-197
• 全文大小：1305 K

文摘

The concentration of cysteine protease inhibitor cystatin C was determined in sera from 59 patients with non-Hodgkin B-cell lymphoma using ELISA. The sera from 43 age and sex matched healthy blood donors served as controls. Cystatin C was significantly increased in sera of patients without therapy (mean 1136 ± SE 105.7 ng/ml, p = 0.00001) and with therapy (mean 1073 ± 52 ng/ml, p = 0.001) compared to controls (mean 819 ± 28 ng/ml). The highest levels were determined in sera of patients with a relapse (mean 1680 ± 196 ng/ml). By using immunofluorescence staining and confocal microscopy we determined immature dendritic cells as a major population of cystatin C positive cells in affected lymph nodes. Our study reports for the first time that cystatin C is a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.